Aytu BioPharma, Inc.
AYTU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $14 | $15 | $18 | $16 |
| % Growth | -8.2% | -18% | 13.8% | – |
| Cost of Goods Sold | $5 | $5 | $6 | $5 |
| Gross Profit | $9 | $10 | $13 | $11 |
| % Margin | 66.1% | 67.8% | 69.4% | 66.5% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $5 | $4 | $4 | $4 |
| SG&A Expenses | $10 | $8 | $9 | $10 |
| Sales & Mktg Exp. | $5 | $5 | $5 | $5 |
| Other Operating Expenses | $0 | $9 | $1 | $2 |
| Operating Expenses | $11 | $18 | $10 | $12 |
| Operating Income | -$2 | -$8 | $2 | -$2 |
| % Margin | -10.8% | -50.4% | 13.1% | -10.4% |
| Other Income/Exp. Net | $3 | -$12 | $1 | $2 |
| Pre-Tax Income | $2 | -$19 | $4 | $0 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | $2 | -$20 | $4 | $1 |
| % Margin | 14.1% | -130.9% | 21.6% | 4.9% |
| EPS | -0.08 | -2.92 | 0.65 | 0.02 |
| % Growth | 97.3% | -549.2% | 3,150% | – |
| EPS Diluted | -0.08 | -2.92 | 0.21 | -0.26 |
| Weighted Avg Shares Out | 9 | 7 | 6 | 6 |
| Weighted Avg Shares Out Dil | 19 | 7 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $3 | -$17 | $6 | $3 |
| % Margin | 23.6% | -115.1% | 32.7% | 16.2% |